On April 6, 2017, the Institute for Patient Access convened the second annual National Policy and Advocacy Summit on Biologics and Biosimilars in Washington, DC. Patients, government representatives, physicians and advocates explored throughout the day-long event how more biological options present both new challenges and new possibilities for treatment.
The event was co-sponsored by the Alliance for Patient Access and the Biologics Prescribers Collaborative.
The summit examined policies that shape access to biologics and biosimilars — such as approval, therapeutic switching and health plan barriers — as well as their impact on patients.
The day’s discussions made one point clear: a handful of breakthrough medicines has quickly ballooned into a robust class of powerful treatments, and advocates are hard at work to keep those medicines accessible to the patients who need them.
